Cyclic phosphatidic acid inhibits the secretion of vascular endothelial growth factor from diabetic human coronary artery endothelial cells through peroxisome proliferator-activated receptor gamma

Mol Cell Endocrinol. 2015 Sep 5:412:320-9. doi: 10.1016/j.mce.2015.05.021. Epub 2015 May 22.

Abstract

Atherosclerosis is a disease characterized by building up plaques formation and leads to a potentially serious condition in which arteries are clogged by fatty substances such as cholesterol. Increasing evidence suggests that atherosclerosis is accelerated in type 2 diabetes. Recent study reported that high level of alkyl glycerophosphate (AGP) was accumulated in atherosclerotic lesions. The presence of this phospholipid in mildly oxidized low-density lipoprotein (LDL) is likely to be involved in atherogenesis. It has been reported that the activation of peroxisome proliferator-activated receptor gamma plays a key role in developing atherosclerosis. Our previous result indicates that cyclic phosphatidic acid (cPA), one of bioactive lipids, potently suppresses neointima formation by inhibiting the activation of peroxisome proliferator-activated receptor gamma (PPARγ). However, the detailed mechanism is still unclear. In this study, to elucidate the mechanism of the cPA-PPARγ axis in the coronary artery endothelium, especially in patients with type 2 diabetes, we investigated the proliferation, migration, and secretion of VEGF in human coronary artery endothelial cells from diabetes patients (D-HCAECs). AGP induced cell growth and migration; however, cPA suppressed the AGP-elicited growth and migration in D-HCAECs. Moreover, AGP increased VEGF secretion from D-HCAECs, and this event was attenuated by cPA. Taken together, these results suggest that cPA suppresses VEGF-stimulated growth and migration in D-HCAECs. These findings could be important for regulatory roles of PPARγ and VEGF in the vascular processes associated with diabetes and atherosclerosis.

Keywords: Cyclic phosphatidic acid; Diabetic human coronary artery endothelial cells; Peroxisome proliferator-activated receptor gamma; VEGF.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Atherosclerosis / metabolism
  • Atherosclerosis / pathology
  • Cell Movement
  • Cell Proliferation
  • Cells, Cultured
  • Coronary Vessels / pathology*
  • Diabetes Mellitus, Type 2 / metabolism
  • Diabetes Mellitus, Type 2 / pathology
  • Endothelial Cells / drug effects
  • Endothelial Cells / metabolism*
  • Heterocyclic Compounds, 1-Ring / pharmacology
  • Humans
  • PPAR gamma / physiology*
  • Phosphatidic Acids / pharmacology*
  • Vascular Endothelial Growth Factor A / metabolism*

Substances

  • Heterocyclic Compounds, 1-Ring
  • PPAR gamma
  • Phosphatidic Acids
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A